Targeting Neuroinvasion by SARS-CoV-2: Emerging Trends in Drug and Antibody Delivery to Combat COVID-19

Overview

Journal ACS Chem Neurosci

Publisher American Chemical Society

Specialty Neurology

Date 2021 Jul 6

PMID 34228437

Citations 3

Authors

Abdul Mannan Baig

Affiliations

Soon will be listed here.

Abstract

Because SARS-CoV-2 uses the nasal cavity as a major route of entry to the human body, nasal administration of drugs and antibodies directed against the virus can prove to be effective for not only pulmonary COVID-19 but also prevention of potential early neuroinvasion caused by this virus. With recent reports of the potential application of antibody-laden nasal spray for the treatment of COVID-19, proposed here is the use of drugs recently proven to be effective against SARS-CoV-2 to be administered via inhalation route using a modified transcribrial device reported previously for its use against , to target SARS-CoV-2 in our fight against COVID-1.

Citing Articles

Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models.

Han Q, Wang S, Wang Z, Zhang C, Wang X, Feng N Virol Sin. 2023; 38(5):787-800.

PMID: 37423308 PMC: 10590698. DOI: 10.1016/j.virs.2023.07.003.

Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection.

Li E, Han Q, Bi J, Wei S, Wang S, Zhang Y Front Immunol. 2023; 14:1066730.

PMID: 36875106 PMC: 9981790. DOI: 10.3389/fimmu.2023.1066730.

Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration.

Seow H, Liao Q, Lau A, Leung S, Yuan S, Lam J Int J Pharm. 2022; 619:121704.

PMID: 35358643 PMC: 8958263. DOI: 10.1016/j.ijpharm.2022.121704.